RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer.

Abstract

Alternatively spliced forms of fibronectin, called oncofetal fibronectin, are aberrantly expressed in cancer, with little to no expression in normal tissue, making them attractive biomarkers to exploit for tumor-targeted therapeutics and diagnostics. While prior studies have explored oncofetal fibronectin expression in limited cancer types and limited sample sizes, no studies have performed a large-scale pan-cancer analysis in the context of clinical diagnostics and prognostics to posit the utility of these biomarkers across multiple cancer types. In this study, RNA-Seq data sourced from the UCSC Toil Recompute project were extracted and analyzed to determine the correlation between the expression of oncofetal fibronectin, including extradomain A and extradomain B fibronectin, and patient diagnosis and prognosis. We determined that oncofetal fibronectin is significantly overexpressed in most cancer types relative to corresponding normal tissues. In addition, strong correlations exist between increasing oncofetal fibronectin expression levels and tumor stage, lymph node activity, and histological grade at the time of diagnosis. Furthermore, oncofetal fibronectin expression is shown to be significantly associated with overall patient survival within a 10-year window. Thus, the results presented in this study suggest oncofetal fibronectin as a commonly upregulated biomarker in cancer with the potential to be used for tumor-selective diagnosis and treatment applications.

• Authors: Ryan C Hall, Amita M Vaidya, William P Schiemann, Quintin Pan, Zheng-Rong Lu
• Journal: Cells (Cells) Vol. 12 Issue 5 (02 21 2023) ISSN: 2073-4409 [Electronic] Switzerland
• PMID: 36899821 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Fibronectins
• FN1 protein, human

Topics

• Humans
• Extracellular Matrix (metabolism)
• Fibronectins (metabolism)
• Neoplasms
• RNA-Seq